New Enterprise Associates
http://www.nea.com/Home/New Enterprise Associates is a venture capital firm based in Baltimore, MD. The firm has backed more than 160 companies that have gone public and invested in more than 230 companies that have been successfully merged or acquired. NEA focuses its investments in the information technology, healthcare, and energy technology industries. While NEA makes a majority of its investments in the United States, the firm invests around the world in China and India. The firm was founded in 1978.
View Older Stories View More Recent Stories
-
TMRW Sports Completes Series A Investment Round, Co-led by Dynasty Equity and Connect Ventures
-
Decagon raises $35 million for AI-powered customer service
-
NEA Appoints Andrew Schoen and Blake Wu to Senior Investing Team Roles, Promotes Alex Sharata to Partner
-
PostgreSQL is Now Faster than Pinecone, 75% Cheaper, with New Open Source Extensions
-
Anterior Secures $20 Million Series A to Unlock Administrative Efficiencies for Healthcare Payers
-
Amber Therapeutics Closes $100 Million Series A Financing to Advance Breakthrough Amber-UI Neuromodulation Therapy for Mixed Urinary Incontinence towards US FDA Approval
-
Stride and Roadie Partner to Empower Drivers with Financial Tools
-
NODAR Transforms Automated Parking By Eliminating The Need For Ultrasonic Sensors And Providing Detailed 3D Surroundview Maps
-
Form SC 13D/A Trevi Therapeutics, Inc. Filed by: New Enterprise Associates 16, L.P.
-
Form SC 13D/A Marker Therapeutics, Filed by: New Enterprise Associates 16, L.P.
-
Form SC 13D/A BuzzFeed, Inc. Filed by: NEW ENTERPRISE ASSOCIATES 13 LP
-
Form SC 13D/A BuzzFeed, Inc. Filed by: NEW ENTERPRISE ASSOCIATES 13 LP
-
Form SC 13D/A SYNLOGIC, INC. Filed by: New Enterprise Associates 14, L.P.
-
Form SC 13D/A ZeroFox Holdings, Inc. Filed by: New Enterprise Associates 14, L.P.
-
Form SC 13D/A Monte Rosa Therapeutics, Filed by: New Enterprise Associates 17, L.P.
-
Form SC 13D/A Black Diamond Therapeuti Filed by: New Enterprise Associates 16, L.P.
-
Form SC 13D/A NEXTNAV INC. Filed by: New Enterprise Associates 14, L.P.
-
Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates
-
Form SC 13D/A GLYCOMIMETICS INC Filed by: NEW ENTERPRISE ASSOCIATES 10 L P
-
Form SC 13D/A Reneo Pharmaceuticals, Filed by: New Enterprise Associates 15, L.P.
-
In-House Health Raises $4 Million Seed Round, Unveils AI-Powered Scheduling Platform to Combat Nurse Shortage Crisis
-
Zenas BioPharma Announces Upsized $200 Million Series C Financing to Advance Mid- and Late-Stage Immunology-Focused Clinical Development Programs
-
Form SC 13D/A CHAMPIONS ONCOLOGY, INC. Filed by: New Enterprise Associates 14, L.P.
-
Form SC 13D/A Inventiva S.A. Filed by: New Enterprise Associates 17, L.P.
-
Form SC 13D/A Desktop Metal, Inc. Filed by: New Enterprise Associates 15, L.P.
-
Form SC 13D/A RHYTHM PHARMACEUTICALS, Filed by: NEW ENTERPRISE ASSOCIATES 13 LP
-
SafeBase Raises $33M in Series B to Accelerate Vision for Friction-Free Security Reviews
-
Merge Expands Footprint in Europe, Facilitating Product Integrations for GDPR-Compliant Companies
-
Form SC 13D/A Korro Bio, Inc. Filed by: New Enterprise Associates 17, L.P.
-
Form 144 Tuya Inc./ADR Filed by: New Enterprise Associates 14, L.P.
-
AviadoBio Announces First Patient Treated in ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations
-
Form SC 13D/A NeueHealth, Inc. Filed by: New Enterprise Associates 15, L.P.
-
Stride Launches Utah's First Independent Worker Portable Benefits Contributions Program
-
NeueHealth Enters into Amendment to its Credit Facility
-
Tony Florence and Mohamad Makhzoumi Named Co-CEOs of NEA; Scott Sandell Assumes Role of Executive Chairman & CIO
-
Timescale Acquires PopSQL to Bring a Modern, Collaborative SQL GUI to PostgreSQL Developers
-
Stride Launches First-Ever Independent Worker Contributions Program for Portable Benefits
-
Form SC 13D/A Adaptimmune Therapeutics Filed by: New Enterprise Associates 14, L.P.
-
SpyGlass Pharma Unveils Compelling 1-Year Data of Its Innovative Drug Delivery Platform Implanted During Routine Cataract Surgery in Eyes with Glaucoma
-
Form SC 13D/A Nkarta, Inc. Filed by: New Enterprise Associates 15, L.P.
-
Kaiser Permanente and Town Hall Ventures launch Habitat Health
-
Avenzo Therapeutics Announces $150 Million Oversubscribed Financing To Advance Emerging Oncology Pipeline
-
Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates
-
HEAVY.AI Introduces HeavyIQ, Delivering Powerful Conversational Analytics Focused on Location and Time Data
-
NEA Appoints Lila Tretikov Partner, Head of AI Strategy
-
Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA
-
Regulus Therapeutics (RGLS) Enters $100M Oversubscribed Private Placement
-
Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity
-
Dr. Laura Shawver to be Recognized as 2024 Duane Roth Endowed Award Lecture Recipient at 20th Annual Industry/Academia Precision Oncology Symposium
-
Propense.ai Raises $3M in Seed Funding for AI-Driven B2B Cross-Selling Platform

